Mirjam Zeisel

Title: Mirjam Zeisel: Innovator in Hepatocellular Carcinoma Treatment

Introduction

Mirjam Zeisel is a prominent inventor based in Strasbourg, France. She has made significant contributions to the field of medical research, particularly in the treatment of hepatocellular carcinoma. With a total of 2 patents to her name, her work focuses on innovative therapeutic approaches that address liver diseases.

Latest Patents

Zeisel's latest patents include groundbreaking research on anti-claudin 1 monoclonal antibodies. These antibodies are designed for the prevention and treatment of hepatocellular carcinoma, specifically in patients suffering from liver disease that is not associated with HCV infection or in those who have been cured from HCV infection. The patents detail methods of preventing and treating hepatocellular carcinoma through the administration of these monoclonal antibodies, along with pharmaceutical compositions. Experimental results have been provided using the hepatocarcinoma cell line HuH-7.5.1, showcasing the efficacy of her innovative approach.

Career Highlights

Throughout her career, Mirjam Zeisel has worked with esteemed institutions such as the Institut Hospitalier Universitaire de Strasbourg and the Institut National de la Santé et de la Recherche Médicale. Her dedication to research and innovation has positioned her as a key figure in the medical community, particularly in the realm of cancer treatment.

Collaborations

Zeisel has collaborated with notable professionals in her field, including Thomas Baumert and Eric Robinet. These partnerships have further enhanced her research and contributed to the advancement of her innovative therapies.

Conclusion

Mirjam Zeisel's contributions to the treatment of hepatocellular carcinoma through her patented innovations highlight her role as a leading inventor in medical research. Her work continues to pave the way for new therapeutic options for patients suffering from liver diseases.